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Abnormal Response of Superior Sinoatrial Node to
Sympathetic Stimulation Is a Characteristic Finding in
Patients With Atrial Fibrillation and
Symptomatic Bradycardia
Boyoung Joung, MD, PhD; Hye Jin Hwang, MD; Hui-Nam Pak, MD, PhD;
Moon-Hyoung Lee, MD, PhD; Changyu Shen, PhD; Shien-Fong Lin, PhD; Peng-Sheng Chen, MD
Background—We hypothesized that unresponsiveness of superior sinoatrial node (SAN) to sympathetic stimulation is
strongly associated with the development of symptomatic bradycardia in patients with atrial fibrillation (AF).
Methods and Results—We performed 3D endocardial mapping in healthy controls (group 1, n10) and patients with AF
without (group 2, n57) or with (group 3, n15) symptomatic bradycardia at baseline and during isoproterenol
infusion. Corrected SAN recovery time was abnormal in 0%, 11%, and 36% of groups 1, 2, and 3, respectively
(P0.02). At baseline, 90%, 26%, and 7% (P0.001) of the patients had multicentric SAN activation patterns. For
groups 1, 2, and 3, the median distance from the superior vena cava-right atrial junction to the most cranial earliest
activation site (EAS) was 5.0 (25–75 percentile range, 3.5–21.3), 10.0 (4–20), and 17.5 (12–34) mm at baseline
(P0.01), respectively, and 4.0 (0–5), 5.0 (1–10), and 15.0 (5.4–33.3) mm, respectively, during isoproterenol infusion
(P0.01), suggesting an upward shift of EAS during isoproterenol infusion. However, although the EAS during
isoproterenol infusion was at the upper one third of the crista terminalis in 100% of group 1 and 78% of group 2 patients,
only 20% of group 3 patients showed a move of the EAS to that region (P0.001).
Conclusions—Superior SAN serves as the EAS during sympathetic stimulation in patients without AF and in most patients with
AF without symptomatic bradycardia. In contrast, unresponsiveness of superior SAN to sympathetic stimulation is a
characteristic finding in patients with AF and symptomatic bradycardia. (Circ Arrhythm Electrophysiol. 2011;4:799-807.)
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Sinoatrial node (SAN) automaticity is maintained bysynergistic actions of a voltage clock mediated by
voltage-sensitive membrane ionic currents, such as the hy-
perpolarization-activated pacemaker current,1 and a Ca2
clock mediated by rhythmic spontaneous sarcoplasmic retic-
ulum Ca2 release.2 The Ca2 clock in the superior SAN is
primarily responsible for rate acceleration during sympathetic
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stimulation.3 Unresponsiveness of the Ca2 clock in the
superior SAN to sympathetic stimulation is a characteristic
finding in dogs with atrial fibrillation (AF) and heart fail-
ure.4,5 AF in humans also is associated with significant SAN
dysfunction and tachybradycardia syndrome or sick sinus
syndrome.6,7 If the findings in canine models are applicable to
humans, then the superior SAN in patients without SAN
dysfunction should respond to sympathetic stimulation by
serving as the earliest activation site (EAS). In contrast,
failure of the superior SAN to serve as the EAS during
isoproterenol infusion would be a characteristic finding in
patients with SAN dysfunction. With the development of 3D
endocardial electroanatomical mapping techniques, it is pos-
sible to define the activation patterns within the human atria
to accurately locate the EAS.8 The purpose of the present
study was to use these mapping techniques to determine the
EAS at baseline and during isoproterenol infusion in patients
without AF (presumably normal SAN), in patients with AF
without symptomatic bradycardia, and in patients with both
AF and symptomatic bradycardia. The results were used (1)
to ascertain whether superior (rostral, upward) shift of EAS is
a normal response to isoproterenol infusion in patients with-
out AF, (2) to test the hypothesis that unresponsiveness of the
superior SAN to sympathetic stimulation (superior SAN
dysfunction) is present in patients with AF, and (3) to test the
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hypothesis that superior SAN dysfunction is a more frequent
observation in patients with AF and symptomatic bradycardia




This prospective study was approved by the Clinical Research and
Ethics Committee of the Yonsei University Hospital, Seoul, South
Korea, where all mapping studies were performed. Written informed
consent was obtained from each patient. We excluded patients from
the study if they had a recent (3 months) myocardial infarction,
ongoing myocardial ischemia, heart failure, valvular heart disease, or
ever been treated with amiodarone. All antiarrhythmic medications
(including -blockers and calcium blockers) were suspended 5
half-lives before the study. Group 1 (n10; 6 men; meanSD age,
4012 years) included patients who underwent ablation for parox-
ysmal supraventricular tachycardia (AV-reciprocating tachycardia
with 4 concealed and 3 manifested bypass tract, and 3 AV nodal
reentrant tachycardia) but had no history of AF. Group 2 (n57; 48
men; age, 5412 years) and group 3 (n15; 8 men; age, 617
years) included patients referred to electrophysiological study for the
treatment of symptomatic AF. Group 2 patients had no evidence of
symptomatic bradycardia, and group 3 patients had cardiac syncope,
presyncope, or dizziness associated with either sinus bradycardia
(40 beats/min) (n7) or prolonged sinus pauses (3.0 s) (n8).
Although group 3 patients had indications for pacemaker implanta-
tion,9 only 1 had a pacemaker implanted 3 years before the
electrophysiological study. The remaining patients were referred for
AF ablation partly because the patients or the referring physicians
wanted to avoid pacemaker implantation through ablation-induced
reverse remodeling of the SAN.7
Electrophysiological Study
Electrophysiological studies were performed in the postabsorptive
state. The patients were sedated with midazolam and fentanyl.
Multipolar catheters were positioned as follows: (1) 20-pole catheter
with 2 to 5 2-mm interelectrode spacing in the coronary sinus with
the proximal 10 electrodes positioned at the lateral right atrium (RA)
and (2) 10-pole catheter with 2 to 7 2-mm interelectrode spacing
along the lateral RA. Surface ECG and bipolar endocardial electro-
grams were monitored continuously and stored on a computer-based
digital amplifier/recorder system with optical disk storage for off-
line analysis. Intracardiac electrograms were filtered from 30 to 500
Hz and measured with computer-assisted calipers at a sweep speed of
400 mm/s.
Sinus node function was evaluated as follows. First, baseline sinus
cycle length was determined over 10 consecutive sinus cycles. Second,
SAN conduction time was determined after an 8-beat pacing train using
the following formula: SAN conduction time(returnbasic cycle
length)/2. The SAN conduction time was measured 3 times, and the
averaged value was used for data analyses. Third, corrected SAN
recovery time (CSNRT) was determined after a 30-s drive train at cycle
lengths of 600, 500, and 400 ms, correcting for the baseline cycle length.
At each cycle length, CSNRT was determined 3 times, and the average
value was used for analyses. CSNRT 550 ms was considered
normal.10
Atrial effective refractory periods (ERPs) were measured 3 times
from the distal and proximal coronary sinus and from low and high
lateral RA. The averaged values were used for analyses. Conduction
time was assessed along the coronary sinus and the lateral RA.
Methods for measuring ERP and atrial conduction are described in
the online-only Data Supplement.
Electroanatomic Mapping
The 3D mapping was recorded before ablation in group 1 patients. In
group 2 and group 3 patients, 3D mapping was performed after
circumferential pulmonary vein isolation, linear ablation in the left
atrium, or both. No ablation was performed in the RA or near the SAN.
Electroanatomic maps of the RA were created at baseline and
during isoproterenol infusion using either Ensite NavX (n79) or the
CARTO mapping system (n3). These systems record the 12-lead
ECG and bipolar electrograms filtered at 30 to 200 Hz from the
mapping catheter and the reference electrogram. Fluoroscopy, RA
angiography, CT, and the Ensite NavX or CARTO merging were
used to facilitate mapping of anatomic structures, particularly the
crista terminalis and superior vena cava (SVC)-RA junction, and for
ensuring endocardial contact when individual points were acquired.
High-density mapping was performed along the crista terminalis,
septal RA, and areas of low voltage. Points were acquired if the
stability criteria in space (6 mm) and local activation time (5 ms)
were met.11,12 Editing of points was performed off-line. Local
activation was manually annotated at the beginning of the first rapid
deflection from the isoelectric line on bipolar electrograms. Points
were excluded if they did not conform to the 12-lead ECG P-wave
morphology or if they were 75% of the maximum voltage of the
preceding electrogram. Low-voltage areas were defined as contigu-
ous areas with a bipolar voltage amplitude of 0.5 mV.11,12
The crista terminalis was divided equally into 3 parts (lower, middle,
and superior). The EAS was then assigned to 1 of the 3 locations based
on the 3D maps. The linear distance from the SVC-RA junction to the
most cranial EAS was used as a quantitative measure of EAS location.
To evaluate the SAN activation patterns, the following definitions were
assigned: (1) unicentric, where a single EAS spreads centrifugally to
activate the atria, and (2) multicentric, where 2 origins of impulses
around the SAN with activation time difference of5 ms are separated
by a distance of10 mm.13 Atrial activation patterns were qualitatively
assessed and described using anatomically correct nomenclature. The
mapping was performed both at baseline and during isoproterenol
infusion. Isoproterenol infusion was started at a dose of 7 g/min. The
mapping during isoproterenol infusion was performed at a stable heart
rate 5 minutes after the commencement of isoproterenol infusion.
Statistical Analysis
Continuous variables that are normally distributed are reported as
meanSD or 95% CI. ANOVA was used to compare the means of
continuous variables that are approximately normally distributed
among the 3 groups, and the SD estimate based on the ANOVA was
used to construct the CIs of group means. Continuous variables that
are not normally distributed (the distance from the SVC-RA junction
to the most cranial EAS, CSNRT, and SAN conduction time (SANCT))
are reported as median (25th–75th percentile range) and compared using
the Kruskal-Wallis test. Normality was determined using the
Kolmogorov-Smirnov goodness-of-fit test. Categorical variables are
reported as count (percentage) and compared using Fisher exact test. An
exact 95% CI was calculated for percentage estimates discussed in the
text. SPSS (SSPS Inc; Chicago, IL) software was used to perform all
statistical evaluations. A P0.05 was considered statistically
significant.
The authors had full access to and take full responsibility for the




The comparisons of basic characteristics among the 3 groups
are presented in Table 1. There were more male patients in
group 2 than in group 3. There was no significant difference
in age, indications for electrophysiological study, left atrial
dimension, and left ventricular ejection fraction between
groups 2 and 3.
SAN Response to Sympathetic Stimulation
We analyzed a mean of 17560 points per patient during
sinus rhythm. There were no significant differences in the
number of points analyzed among groups (P0.71). At
baseline, the EAS was multicentric in 9 of 10 (90%) group 1
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patients and located at the superior to middle parts of the
crista terminalis, with the median distances from the SVC-RA
junction to the most cranial EAS of 5.0 mm (3.5–21.3 mm).
During 7 to 10 g/min of isoproterenol infusion, the EAS was
at the superior part of crista terminalis in 10 (100%) group 1
patients. Figure 1A shows a multicentric EAS at baseline
[Figure 1A (a)] within the SVC but not at the crista termina-
lis. The EAS moved to the superior crista terminalis during
isoproterenol infusion [Figure 1A (b)]. The EAS was in the
middle crista terminalis at baseline [Figure 1B (a)] and
moved to the superior crista terminalis during isoproterenol
infusion [Figure 1B (b)] in 1 group 2 patient. Figure 1C
shows a typical example of unresponsiveness of the superior
SAN to isoproterenol infusion in a patient from group 3. The
EAS at baseline [Figure 1C (a)] was ectopic, located in the
anterior free wall of the RA. During isoproterenol infusion of
7 g/min, the EAS moved to the middle crista terminalis
[Figure 1C (b)]. The superior SAN in this patient was always
activated passively without and with isoproterenol infusion.
The EAS during isoproterenol infusion was at the upper
third of the crista terminalis in 10 (100%) group 1 patients,
with the median distances from the SVC-RA junction to the
most cranial EAS of 4.0 mm (0–5 mm) (Table 2). Figure 2
summarizes the unicentric EAS in group 2 and group 3
patients at baseline (Figure 2A) and during isoproterenol
infusion (Figure 2B). Among them, 43 (78%) group 2
patients showed the EAS at the superior margin of the crista
terminalis or SVC during isoproterenol infusion (Table 2). In
contrast, only 3 (20%) group 3 patients had EAS in the
superior part of the crista terminalis during isoproterenol
infusion. The EAS was located significantly more superior
(cranial) in group 2 than in group 3 (P0001). The median
distance from the SVC-RA junction to the most cranial EAS
was 10.0 mm (4–20 mm) for group 2 and 17.5 mm (12–
34 mm) for group 3 (P0.03) (Figure 2C) at baseline. The
distance shortened significantly to 5.0 mm (1–10 mm) in
group 2 (P0.006) and to 15.0 mm (5.4–33.3 mm) in group
3 (P0.004) during isoproterenol infusion (Figure 2B). The
distance from the SVC to the most cranial EAS was longer in
group 3 than in group 2 during isoproterenol infusion
(P0.01).
Activation Rate in Sinus Rhythm
Baseline heart rate was 78 beats/min (95% CI, 68–86
beats/min) in group 1, 80 beats/min (95% CI, 76–83 beats/
min) in group 2, and 62 beats/min (95% CI, 53–71 beats/min)
in group 3 (P0.001) patients. Group 3 patients had a
significantly lower baseline heart rate than group 1 (P0.02)
and group 2 (P0.001) patients. The mean maximum heart
rate during isoproterenol infusion was 129 beats/min (95% CI,
121–137 beats/min) in group 1, 127 beats/min (95% CI, 123–
131 beats/min) in group 2, and 106 beats/min (95% CI, 95–117
beats/min) in group 3 (P0.001) (Table 2). Group 3 patients had
a significantly lower heart rate than group 1 (P0.02) and group
Table 1. Clinical Characteristics
Group 1 (n10) Group 2 (n57) Group 3 (n15) P
Male sex 6 (60) 48 (84) 8 (53) 0.02*
Age, y 40 (32–48) 54 (51–57) 61 (57–65) 0.001
Type of AF
PAF 0 44 (77) 9 (60) 0.001
PeAF 0 13 (23) 6 (40) 0.001
LA dimension, mm 38.5 (36.8–40.0) 40.4 (38.9–41.9) 43.0 (39.9–46.1) 0.14
LVEF, % 64.4 (60.0–68.4) 64.4 (62.7–66.1) 64.1 (61.3–66.6) 0.98
Underlying disease
Heart failure 0 0 0 . . .
Hypertension 0 30 (53) 5 (33) 0.006
Age 75 y 0 2 (4) 0 0.64
Diabetes 0 2 (4) 0 0.74
Stroke 0 3 (6) 2 (13) 0.35
CHADS2 score 0 0.6 (0.4–0.8) 0.3 (0.1–0.5) 0.01
ERP, ms
High RA 223 (204–244) 217 (209–225) 235 (226–245) 0.11
Low RA 232 (216–248) 220 (214–227) 252 (238–266) 0.001*
Proximal CS 234 (214–257) 236 (227–245) 262 (248–277) 0.03*
Distal CS 257 (245–268) 246 (232–262) 258 (246–269) 0.66
RA CV, m/s 1.29 (1.17–1.39) 0.88 (0.80–0.94) 0.64 (0.44–0.89) 0.001*
LA CV, m/s 1.26 (1.17–1.33) 0.08 (1.02–1.13) 0.89 (0.82–0.97) 0.001*
Data are presented as n (%) or as mean (95% CI). AF indicates atrial fibrillation; CHADS2, congestive heart failure,
hypertension, age75 years, diabetes mellitus, and prior stroke or transient ischemic attack; CS, coronary sinus; CV,
conduction velocity; ERP, effective refractory period; LA, left atrium; LVEF, left ventricular ejection fraction; PAF,
paroxysmal atrial fibrillation; PeAF, persistent atrial fibrillation; RA, right atrium.
*Significant between groups 2 and 3 at P0.05.
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2 (P0.001) patients during isoproterenol infusion. At baseline,
a unicentric activation pattern (as shown in Figure 1A) was
identified in 1 (10%; 95% CI, 0.3%–45%), 42 (74%; 95% CI,
60%–84%), and 13 (86%; 95% CI, 60%–98%) patients in
groups 1, 2 and 3, respectively (P0.001). After isoproterenol
infusion, the unicentric activation patterns were observed in 8
(80%; 95% CI, 44%–97%), 52 (94%; 95% CI, 85%–99%), and
12 (80%; 95% CI, 52%–96%) patients in groups 1, 2, and 3,
respectively (P0.13).
The Multicentric Activation Pattern and
Alternating EAS
The multicentric activation pattern was found in all patient
groups (Table 2). Figure 3A shows an example of multicen-
tric activation in a patient from group 2 at a heart rate of 60
beats/min before isoproterenol infusion. This patient had 4
origins of activation. The EASs were located in the anterior
and posterior portion of the crista terminalis, anterior RA, and
lower RA (arrows). Figure 3B (a) shows that the EAS
(arrows) alternated between the superior and inferior parts of
the crista terminalis in a patient from group 2 at a baseline
heart rate of 90 beats/min. The distance between 2 EASs was
56 mm. During 10-g/min isoproterenol infusion, the 2 EASs
also were consistently observed at a heart rate of 180 beats/min,
and the distance between them was reduced to 38 mm [Figure
3B (b)] because of the upward shift of the lower EAS. Alternat-
ing EASs was observed in 1 group 2 patient.
At baseline, multicentric activation patterns were observed
in 9 (90%; 95% CI, 55%–99%), 15 (26%; 95% CI, 16%–
40%), and 1 (7%; 95% CI, 0.2%–32%) patients in groups 1,
2, and 3, respectively (P0.001). Group 2 (P0.008) and
group 3 (P0.005) had a lower number of multicentric
activation patterns than group 1. The number of early sites
was 2.40.7 separated by 20.413.2 mm in group 3 com-
pared with 3.50.6 sites (P0.02) separated by
27.56.5 mm (P0.33) in group 2. Because of frequent
sinus arrests, we tried but failed to determine the exact EAS
in 1 patient in group 3 (Table 2).
The SAN-RA Propagation
The propagation pattern during sinus rhythm was closely
associated with the isoproterenol infusion and EAS location.
When the EAS was located at the middle (n38) and inferior
(n6) parts of the crista terminalis, the propagation pattern
was slow across the crista terminalis (Figure 4A) or septum
(Figure 4B). However, after the EAS located to the superior
crista terminalis at baseline (n30) and during isoproterenol
infusion (n54), the anterior and posterior conduction delay
was not observed (Figure 4C), and the propagation across the
crista terminalis showed no significant delays compared with
propagation along the crista terminalis.
Figure 1. Effects of isoproterenol infusion on earliest activation site (EAS). A, From a group 1 patient, the most cranial EAS at baseline
(a) was in the superior vena cava. The EAS during isoproterenol infusion (b) was at the superior third of the CT. B, Cranial shift of the
EAS in a group 2 patient. The EAS at baseline (a) and during isoproterenol infusion (b) were at the middle and superior parts of CT,
respectively. C, Impaired cranial shift of the EAS in a group 3 patient. The EAS at baseline (a) was ectopic (at the right atrial free wall).
The EAS during isoproterenol infusion (b) was located at the middle third of CT. The superior sinoatrial node in this patient was inactive
with or without isoproterenol. The dashed line marks the CT. CT indicates crista terminalis.
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Normal Superior SAN Activity During Sympathetic
Stimulation in a Patient With RA Scars
Although most of the patients in group 3 had an unresponsive
superior SAN, 3 (20%) had responsive superior SAN. Figure
5 shows an example from a patient with long-standing
persistent AF and symptomatic SAN dysfunction after car-
dioversion. In this patient, termination of AF during catheter
ablation was followed by junctional rhythm at 40 beats/min
[Figure 5A (a)]. There was no SAN activity to compete with
the junctional rhythm. The slow junctional rhythm could have
explained her symptoms; however, the heart rate increased to
110 beats/min during 10-g/min isoproterenol infusion, and
the superior part of the crista terminalis came alive to serve as
the EAS [Figure 5B (a) arrow]. Figure 5B (b) shows (in gray)
that the low-voltage area (0.5 mV) ranged from the middle
to the lower part of the RA and crista terminalis, consistent
with the presence of extensive scar formation.
Corrected SAN Recovery Time
The CSNRT was not different among the 3 groups at all
pacing cycle lengths (online-only Data Supplement Table).
Abnormal CSNRT (550 ms) was found in 0 (0%; 95% CI,
0%–31%), 6 (11%; 95% CI, 4%–22%), and 5 (33%; 95% CI,
Table 2. The Heart Rate and EAS at Baseline and During Isoproterenol Infusion
Group 1 (n10) Group 2* (n57) Group 3 (n15) P
Baseline
Heart rate, beats/min 78 (68–86) 80 (76–83) 62 (53–71) 0.001
EAS
Unicentric 1 (10) 42 (74) 13 (86) 0.001
Superior 0 28 (49) 2 (13)
Middle 1 (10) 14 (25) 8 (53)
Inferior† 0 0 3 (20)
Multicentric 9 (90) 15 (26) 1 (7) 0.001
Sinus pause 0 0 1 (7) 0.10
EAS location, mm†‡ 5.0 (3.5–21.3) 10.0 (4–20) 17.5 (12–34) 0.01
Isoproterenol
Heart rate, beats/min 129 (121–137) 127 (123–131) 106 (95–117) 0.001
EAS
Unicentric 8 (80) 52 (94) 12 (80) 0.13
Superior† 8 (80) 43 (78) 3 (20)
Middle 0 9 (16) 6 (40)
Inferior 0 0 3 (20)
Multicentric 2 (20)§ 3 (6) 2 (13) 0.26
Sinus pause 0 0 1 (7) 0.11
EAS location, mm†‡ 4.0 (0–5) 5.0 (1–10) 15.0 (5.4–33.3) 0.01
Data are presented as n (%) or mean (95% CI), unless otherwise indicated. EAS indicates earliest activation site.
*EAS was not evaluated in 2 patients in group 2 during isoproterenol infusion.
†P wave between groups 2 and 3.
‡EAS location means the median distance (25th–75th percentile range) from the superior vena cava and right atrial
junction to the most cranial EAS.
§All multicentric sites were located at the upper third of the crista terminalis.
Figure 2. The distribution of the unicentric
earliest activation site at baseline (A) and
during isoproterenol infusion (B). C, The dis-
tance from the SVC-RA junction to the most
cranial earliest activation site at baseline
and during isoproterenol infusion. ISO indi-
cates isoproterenol; IVC, inferior vena cava;
RA, right atrial; SVC, superior vena cava.
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12%–62%) patients in groups 1, 2, and 3, respectively, at the
pacing cycle length of 400 ms (P0.02).
Figure 6A and 6B show SAN response to rapid atrial pacing
from group 2 and group 3 patients, respectively. Figure 6C
presents the dot plots of the CSNRT from 2 groups, showing that
there is a large overlap of CSNRT between the 2 groups.
Other Electrophysiological Differences Between
Groups 2 and 3
The ERP and conduction velocity of the 3 groups are
described in Table 1. ERPs were longer in group 3 than in
group 2 at both high and low RA sites. Although the ERP of
the proximal coronary sinus was longer in group 3 than in
group 2, the distal coronary sinus showed no difference
between group 3 and group 2. There was significant prolon-
gation in the RA conduction velocity in group 3 compared
with group 2. Left atrial conduction velocity along the
coronary sinus catheter also was significantly longer in group
3 compared with group 2 at the pacing cycle length of 600
ms. RA low-voltage area was significantly larger in group 3
(5829%) than in group 2 (3830%, P0.01).
Normalization of SAN Function After AF Ablation
After radiofrequency catheter ablation of AF, sinus rhythm was
maintained in 13 of the 15 group 3 patients (87%; 95% CI,
60%–68%), including 4 (27%; 95% CI, 8%–55%) patients
taking antiarrhythmic drugs during 10 months (25th–75th per-
centile range, 6–14 months) of follow-up. Excluding 1 patient
with a previous pacemaker implantation and 2 patients with AF,
we compared the Holter monitoring before and after ablation of
AF in 12 group 3 patients. Compared with that before baseline,
maximum sinus pause shortened from 5.03.1 to 2.01.1 s
(P0.03), and minimum heart rate increased from 30.68.4 to
47.416.6 beats/min (P0.03). Baseline symptoms of brady-
cardia (sinus pause3 s) persisted in 2 patients with paroxysmal
attacks of AF. There were no documented symptomatic brady-
cardia episodes in the other patients.
Comparative Efficacy of Testing for
Symptomatic Bradycardia
We analyzed the comparative efficacy of CSNRT and 3D
mapping in differentiating group 2 and group 3 patients. CSNRT
550 ms at 400 ms pacing cycle length is considered a positive
CSNRT test. The failure of superior SAN to serve as the EAS
during isoproterenol infusion is considered a positive 3D map-
ping test. The sensitivity, specificity, positive predicative effi-
cacy, and negative predicative efficacy of the CSNRT test were
35%, 89%, 45%, and 84%, respectively, and of the 3D mapping
test, 78%, 78%, 47%, and 93%, respectively. The 3D mapping
test is twice as sensitive but slightly less specific than the
CSNRT test in detecting patients with AF and symptomatic
bradycardia. However, the predictive efficacies of these 2 tests
are comparable.
Discussion
We found that the majority of EASs during sinus rhythm are
located along the crista terminalis, but the exact location of an
EAS is highly variable. The EAS at baseline can be found as
Figure 3. Examples of multicentric and alternating earliest activation sites (EASs). A, Multiple EASs were found in the anterior and pos-
terior portion of CT, anterior right atrium, and lower right atrium (arrows). B, Alternating EAS at superior (left) to inferior (right) CT at
baseline (a) and during isoproterenol infusion (b). Shown are the activation maps and electrograms. The asterisk marks the EAS of CT.
The dashed line marks the CT. Abbreviation as in Figure 1.
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high as within the SVC and as low as 56 mm from the
SVC-RA junction. In the majority of patients without AF and
in approximately one half of the patients with AF but without
symptomatic bradycardia, the EAS was located in the superior
third of the SAN at baseline. During isoproterenol infusion, the
superior SAN invariably served as the EAS in all patients
without AF and in three fourths of patients with AF but without
symptomatic bradycardia. On the other hand, in patients with
both AF and symptomatic bradycardia, the EAS was usually
located in the mid-SAN at baseline and rarely moved to the
Figure 4. The EAS and propagation pattern. A, The EAS was located at the posterior side of the middle part of the CT. The anterior
conduction was delayed at the CT. B, The posterior conduction was delayed at the septum. C, The EAS was located at the superior
vena cava and right atrial junction, showing no delay in anterior conduction pathways. Activation maps and electrograms are shown.
The asterisk marks the EAS of the CT. The dashed line indicates the location of the CT. EAS indicate earliest activation site. Other
abbreviation as in Figure 1.
Figure 5. Responsive superior sinoatrial
node during isoproterenol infusion in a
50-year-old woman with long-standing
persistent atrial fibrillation and sinoatrial
node dysfunction. A, Junctional rhythm of
40 beats/min after termination of AF (a). A
sinus P wave appeared and the sinus rate
increased to 110 beats/min during isopro-
terenol infusion of 10 g/min (b). B, Right
atrial activation map during isoproterenol
infusion (a). The superior part of the crista
terminalis is the earliest activation site
(arrow) (a). The right atrial voltage map (b)
shows low voltage in the middle and
lower parts of the right atrium and crista
terminalis, as indicated in gray (0.5 mV).
The dashed line indicates the location of
the crista terminalis.
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superior SAN during isoproterenol infusion. If a superior shift of
the EAS during isoproterenol infusion is used as a test to identify
patients with symptomatic bradycardia, then the test has a
sensitivity of 78%. In comparison, sensitivity of CSNRT was
only 35%. We conclude that a superior shift of EAS is a normal
response to isoproterenol infusion in patients without AF and in
a majority of patients with AF but no symptomatic bradycardia.
In comparison, the unresponsiveness of superior SAN to serve as
an EAS during sympathetic stimulation (superior SAN dysfunc-
tion) is a common finding among patients with both AF and
symptomatic bradycardia.
EAS and Sympathetic Tone
Schuessler et al14 reported that in a canine model, sympathetic
stimulation in general tends to induce a cranial shift in the
location of the pacemaker within the pacemaker complex.
Although an upward shift of EAS has not been confirmed in
humans by 3D mapping, the downward shift of EAS has been
reported in patients after esmolol infusion.8 Taken together,
the canine and human studies show that superior SAN is
primarily responsible for heart rate acceleration during sym-
pathetic stimulation in patients with normal SAN function.
SAN Function in Patients With AF and
Symptomatic Bradycardia
Sick sinus syndrome is an abnormality involving the gener-
ation of the action potential by the SAN and is characterized
by an atrial rate inappropriate for the physiological require-
ments. AF is associated with significant electrophysiological
and structural remodeling and often is associated with sick
sinus syndrome.6,7 In dogs, persistent (2 weeks) rapid atrial
pacing and chronic AF resulted in SAN dysfunction, as
evidenced by prolongation of the SAN recovery time and a
decrease in intrinsic heart rate.15 SAN dysfunction has been
reported in humans with AF6,16 and may be reversible after
successful AF ablation.7 Consistent with that found in a
canine model,4 patients with AF in the present study had
impaired heart rate acceleration and absence of upward shift
of the EAS during isoproterenol stimulation. These findings
suggest that Ca2 clock malfunction underlies these abnormal
physiological responses to isoproterenol infusion.
Cranial Shift of the EAS and
SAN-RA Propagation
An alternative mechanism for upward shift of the EAS is the
change of the exit pathway between SAN and RA. Previous
studies have shown that the impulse from the SAN propa-
gates into the RA through an upper and a lower exit site.17 It
is possible that isoproterenol preferentially shifts the exit site
to the upper portion of the SAN. Because the extracellular
electrograms cannot be used to differentiate SAN activation
and RA activation, the shifting of SAN exit sites and the
shifting of the actual pacemaking sites may look the same on
the 3D map. The data from the present study cannot be used
to differentiate these 2 mechanisms, but we show that in 1
patient with extensive RA fibrosis and junctional rhythm at
baseline, isoproterenol infusion reactivated the pacemaker in
the superior SAN. In this patient, changing the SAN-RA exit
pathway is not a mechanism of upward shift of the EAS. In
other patients with an upward shift of EAS during isoproter-
enol infusion, the conduction between SAN and RA occurred
at multiple directions without evidence of conduction delay
along the crista terminalis or septum. Based on these findings
and the mapping of the Ca2 clock activity in canine models,
we propose that the pacemaker hierarchy likely is created by
differential responses of the Ca2 clock to sympathetic tone
at different portions of the SAN.
Unicentric Versus Multicentric Activation
Sanders et al11 reported that multicentric activation is found
both in healthy controls and in patients with heart failure.
However, the EASs were more numerous in controls (average
4 sites) than in patients with heart failure (average 2.5 sites).
They also reported that the SAN complex in patients with
SAN dysfunction more often is unicentric, localized to the
lower crista terminalis at the site of the largest residual
voltage amplitude. Consistent with Sanders et al, we found in
the present study that most group 1 patients had a multicentric
Figure 6. A, Normal CSNRT. The basic sinus cycle
length and SNRT are 780 ms (left) and 1020 ms
(right), respectively, resulting in a CSNRT of 240
ms. B, Abnormal CSNRT in a patient with tachy-
bradycardia syndrome. The basic sinus cycle
length and SNRT are 1000 ms (left) and 5800 ms
(right), respectively, resulting in a CSNRT of 4800
ms. The upper and lower tracings are the V1 lead
and RA electrogram, respectively. C, Dot plots of
the CSNRT from group 2 and 3 at each PCL,
showing large overlaps between the 2 groups. The
dashed line shows the CSNRT of 550 ms. CSNRT
indicates correct sinoatrial node recovery time;
PCL, pacing cycle length. Other abbreviation as in
Figure 2.
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SAN activation pattern and that the number of EASs in group
2 and group 3 patients was lower than that in group 1 patients.
A reduction of the EAS suggests that there are fewer back-up
pacemaking sites to respond to sympathetic stimulation,
which could be a sign of SAN dysfunction.
Conclusions
The superior SAN serves as the EAS during sympathetic
stimulation in patients without AF and in most patients with
AF but without symptomatic bradycardia. In contrast, unre-
sponsiveness of the superior SAN to sympathetic stimulation
is a characteristic finding in patients with AF and symptom-
atic bradycardia. Three-dimensional mapping is a more-
sensitive test than CSNRT in identifying patients with AF and
symptomatic bradycardia.
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CLINICAL PERSPECTIVE
Sinoatrial node (SAN) automaticity is maintained by synergistic actions of a voltage clock mediated by voltage-sensitive
membrane ionic currents, such as the hyperpolarization activated pacemaker current, and a Ca2 clock mediated by rhythmic
spontaneous sarcoplasmic reticulum Ca2 release. The Ca2 clock in the superior SAN is primarily responsible for rate
acceleration during sympathetic stimulation. In a canine model of atrial fibrillation (AF) and SAN dysfunction, the Ca2 clock
in the superior SAN was not responsive to sympathetic stimulation. However, the mechanism of SAN dysfunction in humans
is not fully understood. Using 3D mapping techniques to determine the earliest activation site at baseline and during isoproterenol
infusion, we found that the superior SAN serves as the earliest activation site during sympathetic stimulation in patients without
AF and in most patients with AF without a history of symptomatic bradycardia. In contrast, unresponsiveness of the superior
SAN to sympathetic stimulation was a characteristic finding in patients with AF with a history of symptomatic bradycardia. If
a superior shift of the earliest activation site during isoproterenol infusion is used as a test to identify patients with symptomatic
bradycardia, then the test has a sensitivity and specificity of 78% and 78%, respectively. The results suggest that the
unresponsiveness of the superior SAN to serve as the earliest activation site during sympathetic stimulation (superior SAN
dysfunction) is a mechanism of SAN dysfunction in patients with both AF and symptomatic bradycardia. The unresponsiveness
of the superior SAN to sympathetic stimulation might be used as a test to detect patients with SAN dysfunction.
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SUPPLEMENTAL MATERIAL  
 
Supplementary Methods 
Effective Refractory Period 
Atrial effective refractory periods (ERPs) were evaluated with S2 strength at twice 
diastolic threshold current (for a pacing threshold of <2 mA) after 8 S1 paced beats at cycle 
lengths of 600, 500, and 400 ms. An incremental technique was used, starting with an S1- S2 
coupling interval of 150 ms. The coupling interval was then increased with 5 ms increments 
until S2 captured the atria. The ERP was defined as the longest coupling interval that failed to 
capture the atria. ERP was measured from the distal and proximal coronary sinus and from 
low and high lateral RA for 3 times. The averaged values were used for analyses.   
Atrial Conduction 
Conduction velocity was assessed along the coronary sinus by pacing from the distal 
bipole (1-2) of the coronary sinus catheter and measuring the activation time at the proximal 
bipole (9-10), and along the lateral RA by pacing from the distal bipole (1-2) of the lateral 
RA catheter and measuring time to activate bipoles 9-10. At both sites, conduction was 
measured at pacing cycle lengths of 600, 500, and 400 ms during stable capture. Conduction 
time was determined 10 times at each cycle length and the average value was used for 
analyses.  
 
Supplementary Table. CSNRT, Number of patients with abnormal CSNRT (> 550ms), and 
SANCT. 
 Group 1 Group 2 Group 3 P-value 
CSNRT, ms, (median 
(25-75% percentile)) 
    
PCL 600 ms 299 (215-364) 291 (210-402) 356 (138-621) 0.65 
PCL 500 ms* 248 (183-314) 305 (140-405) 383 (224-736) 0.12 
PCL 400 ms* 169 (151-313) 285 (98-440) 341 (220-723) 0.14 
No. Patients with 
CSNRT > 550 ms, n 
    
PCL 600 ms* 0 7 (12) 5 (36) 0.03 
PCL 500 ms* 0 4 (7) 5 (36) 0.005 
PCL 400 ms* 0 6 (11) 5 (36) 0.02 
SANCT, ms     
PCL 600 ms* 141 (56-189) 130 (78-173) 216 (126-258) 0.02 
PCL 500 ms 133 (81-177) 135 (77-180) 116 (82-218) 0.97 
PCL 400 ms 115 (84-151) 128 (70-155) 82 (32-135) 0.43 
CSNRT, corrected sinus node recovery time; PCL, pacing cycle length; SANCT, sinoatrial 
node conduction time. 
* P-value was significant between groups 2 and 3 (p<0.05). 
 
